This clinical trial is focused on studying a condition called Ocular Myasthenia Gravis, which affects the muscles around the eyes, leading to weakness and fatigue. The study will evaluate a treatment called Efgartigimod, also known by its code name ARGX-113. Efgartigimod is administered as a solution for injection using a pre-filled syringe. The trial will compare the effects of Efgartigimod with a placebo, which is a substance with no active medication, to determine its effectiveness and safety in treating this condition.

The purpose of the study is to assess how well Efgartigimod works in improving symptoms of Ocular Myasthenia Gravis and to ensure it is safe for use. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will monitor changes in the participants’ symptoms over a period of time, focusing on improvements in muscle strength around the eyes and overall well-being.

Throughout the study, participants will be closely observed for any side effects or changes in their condition. The trial aims to provide valuable information on the potential benefits of Efgartigimod for individuals with Ocular Myasthenia Gravis, contributing to the development of effective treatments for this condition. The study is designed to ensure the safety and well-being of all participants while gathering important data on the treatment’s impact.